Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
Casino Giant Galaxy Entertainment’s H1 Profit Drops 7% as High-Rollers Stay Away
Chinese App-Makers Smell Opportunities in Strict Trash-Sorting Rules
Tencent Posts 35% Profit Rise on Reviving Game Releases
LATEST
Cathay Pacific CEO Hogg Resigns Amid Hong Kong Protests
Ninebot’s New Scooter Can Drive Itself Back to Charging Stations
Oppo to Unveil New Smartphone With 20x Zoom
Chinese Companies Usher in Age of Synthetic Meat
Record-Smashing Chinese Animation to Get Overseas Releases
WTO to Arbitrate China’s Complaints About U.S. Solar-Cell Tariffs
Vipshop Stock Soars After Q2 Results Beat Expectations
Japan Replaces China as Largest Holder of U.S. Government Debt
Huawei’s First 5G Commercial Phone Gets Warm Response Despite Limited Networks
AI Startup Plans IPO at Value of at Least $1 Billion — in China
Alibaba Q2 Revenue Jumps 42%, Beating Estimates But Slower Than Year Earlier
Baidu’s $66 Billion Dive Knocks It Out of China’s Internet Top 5
Beijing Grants Foreign Investors Wider Access to Entertainment Industry
Tencent-Backed Maoyan Turns Profit on Strong Ad Growth
Chinese App-Makers Smell Opportunities in Strict Trash-Sorting Rules
Casino Giant Galaxy Entertainment’s H1 Profit Drops 7% as High-Rollers Stay Away
Chinese Internet Sector Grows 17.9% Year-on-Year: MIIT
Xiaomi Receives Licenses for Second 5G Phone
Coal Industry Looks to Robots for Increased Safety
No Investor Love for Tencent, Lenovo and Luckin in Latest Reports
China Approves New Rheumatoid Arthritis Drug

By Zhao Runhua and Di Ning / Jul 24, 2019 04:53 AM / Business & Tech

Photo: Bloomberg

Photo: Bloomberg

Another global pharmaceutical company won government approval to sell a drug to sufferers of rheumatoid arthritis (RA) in China after multiple international companies announced approvals to offer treatments to millions of patients.

Belgium-based UCB was cleared to provide treatment for moderate-to-severe RA patients with Cimzia, a drug the company submitted in 2018 to China’s National Medical Product Administration for review, according to an official release. UCB said Cimzia is its first biologic therapy approved for the China market. The treatment is widely used for cancer and other conditions to restore patients’ immune systems. 

RA is a chronic illness in which a patient’s immune system causes pain by attacking joints. The cause remains unknown. According to a report published by the Chinese Medical Association’s RA group, the Chinese mainland now has around 5 million RA patients.

The effective date and pricing for Cimzia’s sales in China were not available.

An RA drug co-developed by Lilly and Incyte won approval from the Chinese government earlier this month. A Lilly spokesperson told Caixin the price would be decided with careful consideration of Chinese patients’ purchasing capability. Lilly also said it hoped China’s national medical insurance program could support patients’ use of the drug.

Contact reporter Zhao Runhua (runhuazhao@caixin.com)

Share this article
Open WeChat and scan the QR code
Copyright © 2019 Caixin Global Limited. All Rights Reserved.